CY1119308T1 - Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου - Google Patents

Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου

Info

Publication number
CY1119308T1
CY1119308T1 CY20171100902T CY171100902T CY1119308T1 CY 1119308 T1 CY1119308 T1 CY 1119308T1 CY 20171100902 T CY20171100902 T CY 20171100902T CY 171100902 T CY171100902 T CY 171100902T CY 1119308 T1 CY1119308 T1 CY 1119308T1
Authority
CY
Cyprus
Prior art keywords
infections
dab
trp
individual compounds
diseases
Prior art date
Application number
CY20171100902T
Other languages
English (en)
Inventor
Glenn E Dale
Daniel Obrecht
Original Assignee
Polyphor Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyphor Ag filed Critical Polyphor Ag
Publication of CY1119308T1 publication Critical patent/CY1119308T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406Antibiotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Ένας νέος συνδυασμός που περιλαμβάνει ένα πεπτιδομιμητικό β-φουρκέτας του τύπου κυκλo(-Thr-Trp-lle-Dab-Orn-DDab-Dab-Trp-Dab-Dab-Ala-Ser-DPro-Pro) (I), και μία ένωση της τάξης γλυκυλκυκλίνης, ειδικά τιγεκυκλίνη, που καθιστά δυνατό τον θεραπευτικό έλεγχο ειδικών βακτηριακών μολύνσεων σε ανθρώπους ή ζώα σε δόσεις των ξεχωριστών ενώσεων χαμηλότερων εν συγκρίσει προς τις εκάστοτε ενώσεις όταν χορηγούνται μόνες. Ο συνδυασμός μπορεί να χρησιμοποιείται ως ένα φάρμακο για την αγωγή, π.χ., μολύνσεων του δέρματος ή των μαλακών ιστών, μολύνσεων του οφθαλμού, του αυτιού, της κυκλοφορίας του αίματος ή ενδοκοιλιακών μολύνσεων σχετικών με αναπνευστικά νοσήματα, με νοσήματα των οστών, με καρδιαγγειακά νοσήματα, με ουρογεννητικά νοσήματα ή με γαστρεντερικά νοσήματα.
CY20171100902T 2012-08-08 2017-08-28 Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου CY1119308T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12005744 2012-08-08
EP13745432.8A EP2882770B1 (en) 2012-08-08 2013-08-07 Combinations with a backbone-cyclized peptide
PCT/EP2013/066530 WO2014023757A1 (en) 2012-08-08 2013-08-07 Combinations with a backbone-cyclized peptide

Publications (1)

Publication Number Publication Date
CY1119308T1 true CY1119308T1 (el) 2018-02-14

Family

ID=46796226

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100902T CY1119308T1 (el) 2012-08-08 2017-08-28 Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου

Country Status (26)

Country Link
US (1) US9775877B2 (el)
EP (1) EP2882770B1 (el)
JP (2) JP6486270B2 (el)
KR (1) KR102167324B1 (el)
CN (1) CN104684925B (el)
AU (1) AU2013301567B2 (el)
BR (1) BR112015002727B1 (el)
CA (1) CA2879207C (el)
CY (1) CY1119308T1 (el)
DK (1) DK2882770T3 (el)
EA (1) EA030077B1 (el)
ES (1) ES2639165T3 (el)
HK (1) HK1207866A1 (el)
HR (1) HRP20171299T1 (el)
HU (1) HUE035891T2 (el)
IL (1) IL236697B (el)
LT (1) LT2882770T (el)
MX (2) MX366997B (el)
NZ (1) NZ703729A (el)
PL (1) PL2882770T3 (el)
PT (1) PT2882770T (el)
RS (1) RS56249B1 (el)
SG (1) SG11201500216TA (el)
SI (1) SI2882770T1 (el)
WO (1) WO2014023757A1 (el)
ZA (1) ZA201500278B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2349879T3 (es) 2007-02-28 2011-01-12 Polyphor Ltd. Peptidomiméticos fijados sobre patrón.
CN104684925B (zh) * 2012-08-08 2021-11-30 波利弗尔股份公司 含有主链环化肽的组合
EP4247338A2 (en) * 2020-11-23 2023-09-27 Spexis AG Compositions of a beta-hairpin peptidomimetic and aerosol dosage forms thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4310106B2 (ja) 2001-02-23 2009-08-05 ポリファー リミテッド 抗菌活性を有するテンプレート結合ペプチド擬似体
BRPI0215855B1 (pt) 2002-08-20 2016-12-13 Polyphor Ltd peptídeos cíclicos ligados à matriz com ação antimicrobiana
WO2007079597A1 (en) 2006-01-16 2007-07-19 Polyphor Ltd. Template - fixed peptidomimetics with antimicrobial activity
ES2349879T3 (es) * 2007-02-28 2011-01-12 Polyphor Ltd. Peptidomiméticos fijados sobre patrón.
US20100035845A1 (en) * 2008-08-06 2010-02-11 Wyeth Tigecycline formulations
CN104684925B (zh) * 2012-08-08 2021-11-30 波利弗尔股份公司 含有主链环化肽的组合

Also Published As

Publication number Publication date
NZ703729A (en) 2018-03-23
LT2882770T (lt) 2017-10-10
US9775877B2 (en) 2017-10-03
IL236697B (en) 2020-02-27
EP2882770B1 (en) 2017-05-31
JP6486270B2 (ja) 2019-03-20
KR102167324B1 (ko) 2020-10-20
DK2882770T3 (en) 2017-09-18
US20150216927A1 (en) 2015-08-06
SI2882770T1 (sl) 2017-10-30
BR112015002727B1 (pt) 2022-09-06
EA201590351A1 (ru) 2016-05-31
BR112015002727A2 (pt) 2017-08-08
RS56249B1 (sr) 2017-11-30
MX2019002657A (es) 2019-07-15
ES2639165T3 (es) 2017-10-25
ZA201500278B (en) 2016-01-27
JP2015524460A (ja) 2015-08-24
HUE035891T2 (en) 2018-05-28
HK1207866A1 (en) 2016-02-12
WO2014023757A1 (en) 2014-02-13
MX366997B (es) 2019-08-02
JP2018087191A (ja) 2018-06-07
CN104684925B (zh) 2021-11-30
SG11201500216TA (en) 2015-03-30
AU2013301567A1 (en) 2015-02-05
CA2879207C (en) 2021-02-16
HRP20171299T1 (hr) 2017-10-20
EA030077B1 (ru) 2018-06-29
EP2882770A1 (en) 2015-06-17
IL236697A0 (en) 2015-02-26
MX2015001685A (es) 2015-04-10
KR20150038612A (ko) 2015-04-08
CA2879207A1 (en) 2014-02-13
PL2882770T3 (pl) 2018-01-31
CN104684925A (zh) 2015-06-03
PT2882770T (pt) 2017-09-11
AU2013301567B2 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
EA201791199A1 (ru) Способ лечения болезни альцгеймера
BR112015006623A2 (pt) laquinimod e pridopidina para o tratamento de doenças neurodegenerativas
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
BR112018075300A2 (pt) métodos para tratamento do mal de alzheimer
MX2018012538A (es) Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos.
CY1119308T1 (el) Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
PH12017500392A1 (en) Medical treatments based on anamorelin
EA201891007A1 (ru) Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца
CY1120727T1 (el) Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου
CY1119073T1 (el) Ισομορφες γλυκοζυλιωσης ανθρωπινης ιστικης καλλικρεινης 1
PH12018501769A1 (en) Medicament for treatment of diabetic foot infections
BR112018007374A2 (pt) composição farmacêutica
WO2016066722A3 (en) Bacteriophage combinations for human or animal therapy
BR112017009577A2 (pt) análogos de pantotenamida
BR112014016575A2 (pt) método para o tratamento da doença de lyme
EA202091647A1 (ru) Соединения, композиции и способы лечения заболеваний, связанных с ацидозными или гипоксическими пораженными тканями
CY1119845T1 (el) Ενα γαλακτοκομικο προϊον μειωμενης χοληστερολης για χρηση στην θεραπευτικη αντιμετωπιση και/ή προληψη μιας ασθενειας του ηπατος
Eckmann Thrombocytopenia, fever and chills: 2 case reports
MX2018004295A (es) Compuestos, composiciones farmáceuticas y métodos de uso de agonistas de ppar.
RU2014104644A (ru) Способ повышения эффективности лечения коров, больных острым гнойно-катаральным эндометритом
UA102567U (uk) Спосіб корекції імунної системи телят за умов антибіотикотерапії, при лікуванні респіраторних захворювань запального характеру
EA201692163A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом